Search Results - "Fowler, D.H."

Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation by Bishop, M.R., Dean, R.M., Steinberg, S.M., Odom, J., Pavletic, S.Z., Chow, C., Pittaluga, S., Sportes, C., Hardy, N.M., Gea-Banacloche, J., Kolstad, A., Gress, R.E., Fowler, D.H.

“…A graft-versus-lymphoma effect against diffuse large B-cell lymphoma (DLBCL) is inferred by sustained relapse-free survival after allogeneic stem-cell…”
Get full text

Temsirolimus-resistant, checkpoint-deficient, homeostatic cytokine-responsive autologous TH1/TC1 cells for therapy of relapsed, refractory multiple myeloma (RRMM) by Felizardo, T., Mosquera Limas, S., Zhu, N., Bushera, H., Glass, D., Hari, P., Dhakal, B., Fowler, D.H.

Get full text

Induced hybrid Treg/Th2 RAPA-501 cells for therapy of amyotrophic lateral sclerosis (ALS) by Felizardo, T., Berry, J., Mosquera Limas, S., Zhu, N., Bushera, H., Glass, D., Munshi, P., Rowley, S., Korngold, R., Donato, M., Glass, J., Fowler, D.H.

Get full text

STAT1 Deficiency Fails to Protect Against Murine Chronic GVHD by Foley, J.E, Amarnath, S, Felizardo, T.C, He, A, Fowler, D.H

Get full text

In vivo biologic activity of induced hybrid TREG/Th2 RAPA-501 cells for als therapy: correction of TSCM:TEMimbalance, normalization of IL-6 secretion, and reduction in serum NF-L levels by Felizardo, T., Lum, L.G., Ashmaig, M., Mosquera Limas, S., Zhu, N., Bushera, H., Glass, D., Berry, J., Korngold, R., Donato, M., Glass, J., Munshi, P., Rowley, S., Fowler, D.H.

Get full text

STAT3 Promotes Both Natural and Inducible T Regulatory Cell Plasticity During Murine Acute GVHD by Amarnath, S, Laurence, A.D, Mariotti, J, Foley, J.E, O'Shea, J.J, Fowler, D.H

Get full text

Human T Cell Rapamycin Resistance And Th1/Tc1 Polarization Augment Xenogeneic Graft-Versus-Host Disease by Amarnath, S, Mangus, C.W, Costanzo, C.M, Foley, J.E, Eckhaus, M, Levine, B.L, June, C.H, Fowler, D.H

Get full text

Role of Clinical Laboratory Markers of inflammation in Assessing Chronic Graft Versus Host Disease (cGVHD) Activity and Severity by Grkovic, L, Baird, K, Steinberg, S.M, Pulanic, D, Cowen, E.W, Mitchell, S.A, Williams, K.M, Carpenter, A.E, Wroblewski, S.G, Hakim, F.T, Avila, D.N, Taylor, T.N, Rowley, S.D, Zhang, D, Gea-Banachloche, J.C, Sportes, C, Fowler, D.H, Bishop, M.R, Gress, R.E, Pavletic, S.Z

Get full text

284: Graft Rejection as a Type I Immune Response Amenable to Modulation by Type II Donor T Cells via an “Infectious” Mechanism by Mariotti, J, Foley, J, Amarnath, S, Buxhoeveden, N, Ryan, K, Costanzo, C.M, Fowler, D.H

Get full text

T-Rapa Cell DLI Safely Balances Th1/Th2 Cytokine Activation After Low-Intensity Allogeneic Hematopoietic Cell Transplantation by Fowler, D.H, Mossoba, M.E, Hakim, F.T, Kurlander, R, Gea-Banacloche, J, Sportes, C, Hardy, N.M, Pavletic, S.Z, Steinberg, S.M, Khuu, H.M, Sabatino, M, Stroncek, D.F, Leitman, S.F, Rowley, S.D, Donato, M, Goy, A, Friedman, T.M, Korngold, R, Pecora, A.L, Levine, B.L, June, C.H, Gress, R.E, Bishop, M.R

Get full text

Validation of the National Institutes of Health (NIH) Consensus Criteria for Chronic GVHD (cGVHD) Staging Correlated With Established Indicators of Disease Severity and Prognosis by Baird, K, Steinberg, S.M, Grkovic, L, Pulanic, D, Cowen, E.W, Mitchell, S.A, Williams, K.M, Datiles, M, Fall-Dickson, J.M, Carpenter, A, Avila, D.N, Taylor, T, Urban, A, Joe, G, Comis, L, Berger, A, Stratton, P, Shelhamer, J, Gea-Banacloche, J, Sportes, C, Fowler, D.H, Bishop, M.R, Gress, R.E, Pavletic, S.Z

Get full text

Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity by Grkovic, L, Baird, K, Steinberg, S M, Williams, K M, Pulanic, D, Cowen, E W, Mitchell, S A, Hakim, F T, Martires, K J, Avila, D N, Taylor, T N, Salit, R B, Rowley, S D, Zhang, D, Fowler, D H, Bishop, M R, Gress, R E, Pavletic, S Z

“…Chronic graft-versus-host disease (cGVHD) remains a major cause of non-relapse morbidity and mortality after allogeneic hematopoietic stem cell…”
Get full text

Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD) by Mitchell, S A, Leidy, N Kline, Mooney, K H, Dudley, W N, Beck, S L, LaStayo, P C, Cowen, E W, Palit, P, Comis, L E, Krumlauf, M C, Avila, D N, Atlam, N, Fowler, D H, Pavletic, S Z

“…This study examined factors accounting for functional performance limitations in 100 long-term survivors of allogeneic hematopoietic stem cell transplantation…”
Get full text

NIH response criteria measures are associated with important parameters of disease severity in patients with chronic GVHD by Curtis, L M, Grkovic, L, Mitchell, S A, Steinberg, S M, Cowen, E W, Datiles, M B, Mays, J, Bassim, C, Joe, G, Comis, L E, Berger, A, Avila, D, Taylor, T, Pulanic, D, Cole, K, Baruffaldi, J, Fowler, D H, Gress, R E, Pavletic, S Z

“…Lack of standardized criteria measuring therapeutic response remains an obstacle to the development of better treatments for chronic GVHD (cGVHD). This…”
Get full text

234: Rapamycin generated donor Th2/Tc2 cells prevent graft rejection by inhibition of alloreactivity and not by deletion of alloreactive T cells by Mariotti, J, Foley, J, Wong, E, Borenstein, T, Han, S, Hanson, J, Fowler, D.H

Get full text

336: Relative Contribution of CD127 Negative Selection, Rapamycin, and TGF-β to the Generation of Human Regulatory T Cells that Inhibit Alloreactivity via Dendritic Cell Modulation by Amarnath, S, Foley, J, Mariotti, J, Costanzo, C.M, Ryan, K, Fong, T, Warner, N, Fowler, D.H

Get full text

Engineered human Tmpk fused with truncated cell-surface markers: versatile cell-fate control safety cassettes by Scaife, M, Pacienza, N, Au, B C Y, Wang, J C M, Devine, S, Scheid, E, Lee, C-J, Lopez-Perez, O, Neschadim, A, Fowler, D H, Foley, R, Medin, J A

“…Cell-fate control gene therapy (CFCGT)-based strategies can augment existing gene therapy and cell transplantation approaches by providing a safety element in…”
Get full text

Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients by Foglietta, M, Neelapu, S S, Kwak, L W, Jiang, Y, Nattamai, D, Lee, S-T, Fowler, D H, Sportes, C, Gress, R E, Steinberg, S M, Vence, L M, Radvanyi, L, Dwyer, K C, Qazilbash, M H, Bryant, R N K, Bishop, M R

“…To enhance the therapeutic index of allogeneic hematopoietic SCT (HSCT), we immunized 10 HLA-matched sibling donors before stem cell collection with…”
Get full text

Differential immune responses mediated by adenovirus- and lentivirus-transduced DCs in a HER-2 neu overexpressing tumor model by Felizardo, T C, Wang, J C M, McGray, R A J, Evelegh, C, Spaner, D E, Fowler, D H, Bramson, J L, Medin, J A

“…Recent investigations have demonstrated that adenoviral and lentiviral vectors encoding HER-2 can be utilized in cancer immunotherapy. However, it is not known…”
Get full text

Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation by Fløisand, Y, Brinch, L, Gedde-Dahl, T, Tjønnfjord, G E, Dybedal, I, Holte, H, Heldal, D, Torfoss, D, Aurlien, E, Lauritzsen, G F, Fosså, A, Lehne, G, Baggerød, E, Kvalheim, G, Egeland, T, Bishop, M R, Fowler, D H, Kolstad, A

“…Reduced-intensity conditioning (RIC) allo-SCT is a potentially curative treatment approach for patients with relapsed Hodgkin’s or non-Hodgkin’s lymphoma. In…”
Get full text